Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vir Biotechnology, Inc. VIR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
56/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.29
+111.8%

Vir Biotechnology, Inc. (VIR) is a Biotechnology company in the Healthcare sector, currently trading at $10.05. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is VIR = $21 (+111.8% upside).

Valuation: VIR trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25).

Financials: revenue is $69M, -38.7%/yr average growth. Net income is $438M (loss), growing at -62.7%/yr. Net profit margin is -638.9% (negative). Gross margin is 82.9% (-7.8 pp trend).

Balance sheet: total debt is $187M against $765M equity (Debt-to-Equity (D/E) ratio 0.24, conservative). Current ratio is 5.54 (strong liquidity). Debt-to-assets is 18.6%. Total assets: $1.0B.

Analyst outlook: 10 / 12 analysts rate VIR as buy (83%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 47/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$21.29
▲ 111.84% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Vir Biotechnology, Inc., the average price target is $21.29, with a high forecast of $30.00, and a low forecast of $18.00.
Highest Price Target
$30.00
Average Price Target
$21.29
Lowest Price Target
$18.00

VIR SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 47/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VIR

✓
VALUE Pass
100/100
VIR trades at a trailing Price-to-Earnings (P/E) of -3.1 (S&P 500 average ~25). Forward PEG -0.24 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $21, implying +109% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VIR: -38.7%/yr revenue is, -62.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
VIR: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet VIR: Debt-to-Equity (D/E) ratio 0.24 (conservative), Current ratio is 5.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
47/100
VIR: Gross margin is 82.9% (-7.8 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 47/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 10 / 12 analysts rate VIR as buy (83%). Analyst consensus target is $21 (+109% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VIR: Net profit margin is -638.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.155-10.94
Volume2.64M
Avg Volume (30D)3.58M
Market Cap$1.61B
Beta (1Y)1.66
Share Statistics
EPS (TTM)-3.16
Shares Outstanding$138.52M
IPO Date2019-10-11
Employees408
CEOMarianne De Backer
Financial Highlights & Ratios
Revenue (TTM)$68.56M
Gross Profit$56.85M
EBITDA$-426.09M
Net Income$-437.99M
Operating Income$-468.02M
Total Cash$462.86M
Total Debt$186.91M
Net Debt$-47.2M
Total Assets$1B
Price / Earnings (P/E)-3.2
Price / Sales (P/S)23.43
Analyst Forecast
1Y Price Target$20.00
Target High$30.00
Target Low$18.00
Upside+99.0%
Rating ConsensusBuy
Analysts Covering12
Buy 83% Hold 17% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92764N1028

Price Chart

Track all markets on TradingView
VIR
Vir Biotechnology, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
4.16 52WK RANGE 10.94

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 RETA
RETA
Reata Pharmaceuticals, Inc.
$172.36
+0.02%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.01
+3.68%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message